TORONTO, March 04, 2021 (GLOBE NEWSWIRE) — PsyBio Therapeutics Corp. (TSXV:PSYB) (“ PsyBio” or the “Company”), a leader in the field of psychedelic research and drug development, announces that, subject to the receipt of approval by the TSX Venture Exchange (“TSXV”), it has retained Generation IACP Inc. (“Generation”) to provide market making services with the objective of maintaining a reasonable…


Previous articleRegulatory Approvals Place Numinus Lab at the Forefront of Global Psychedelics Research
Next articleTryp Therapeutics Announces Application to List on OTCQB